Sugi Predict

Sugi Predict / Compounds / SCHEMBL890077

SCHEMBL890077

SCHEMBL890077

Cc1cnc2nc(C(C)C)[nH]c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ HSD17B10 Q99714 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CYP1A2 P05177 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.37
▸ HPGD P15428 2/20 0.37
▸ HTT P42858 2/20 0.37
▸ USP2 O75604 1/20 0.37
▸ ADORA3 P0DMS8 2/20 0.36
▸ ADORA2A P29274 2/20 0.36
▸ ADORA1 P30542 2/20 0.36
▸ ADORA2B P29275 1/20 0.36
▸ BRAF P15056 1/20 0.35
▸ PAK4 O96013 1/20 0.35
▸ CCR1 P32246 1/20 0.34
▸ CCR5 P51681 1/20 0.34
▸ CCR8 P51685 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL798546 0.82 HSD17B10 (0.41) AURKASMN1; SMN2HSD17B10KDM4ELMNA
SCHEMBL22962270 0.81 HSD17B10 (0.40) AURKASMN1; SMN2HSD17B10KDM4ELMNA
SCHEMBL21499437 0.81 HSD17B10 (0.40) AURKASMN1; SMN2HSD17B10KDM4ELMNA
SCHEMBL12980804 0.81 HSD17B10 (0.40) AURKASMN1; SMN2HSD17B10KDM4ELMNA
SCHEMBL10141045 0.78 SCN10A (0.40) AURKASMN1; SMN2HSD17B10KDM4ELMNA
SCHEMBL12232009 0.78 HSD17B10 (0.38) SMN1; SMN2HSD17B10KDM4ELMNAALDH1A1
SCHEMBL2756735 0.77 SMN1; SMN2 (0.67) AURKASMN1; SMN2HSD17B10KDM4ECYP1A2
SCHEMBL26319858 0.77 AURKA (0.40) AURKASMN1; SMN2KDM4ECYP1A2ALDH1A1
SCHEMBL889310 0.76 HSD17B10 (0.39) SMN1; SMN2HSD17B10KDM4ELMNACYP1A2
SCHEMBL15451032 0.74 AURKA (0.49) AURKASMN1; SMN2HSD17B10KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3752498-B1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2023-06-28 — — EP disclosed
US-20210040087-A1 SOMATOSTATIN MODULATORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-02-11 — — US disclosed
US-8221737-B2 Hepatitis C virus inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2012-07-17 — — US disclosed
US-20120172290-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2012-07-05 — — US disclosed
US-20120039848-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2012-02-16 — — US disclosed
US-20110189129-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-08-04 — — US disclosed
US-20110142798-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-06-16 — — US disclosed
US-20110070196-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-03-24 — — US disclosed
US-20110064695-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-03-17 — — US disclosed
US-20110064698-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-03-17 — — US disclosed
US-20110059976-A1 PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2011-03-10 — — US disclosed
US-20110008288-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-01-13 — — US disclosed
US-20100316607-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2010-12-16 — — US disclosed
US-7767687-B2 Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors BIOGEN IDEC MA INC. (US) 2010-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120039848-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 AURKA 3142/4885SMN1; SMN2 4162/4885HSD17B10 581/4885
US-20100316607-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 AURKA 3142/4885SMN1; SMN2 4162/4885HSD17B10 581/4885
US-20110189129-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, HCCS, NSUN2 AURKA 2385/4885SMN1; SMN2 4341/4885HSD17B10 1474/4885
US-20210040087-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 AURKA 4730/4885SMN1; SMN2 1197/4885HSD17B10 3787/4885
US-20110142798-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 AURKA 3142/4885SMN1; SMN2 4162/4885HSD17B10 581/4885
US-20110008288-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 AURKA 3142/4885SMN1; SMN2 4162/4885HSD17B10 581/4885
US-20110070196-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, EIF2AK2, SLC10A1 AURKA 3411/4885SMN1; SMN2 4269/4885HSD17B10 643/4885
US-20110064698-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, EIF2AK2, SLC10A1 AURKA 3411/4885SMN1; SMN2 4269/4885HSD17B10 643/4885
US-20110064695-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, EIF2AK2, SLC10A1 AURKA 3411/4885SMN1; SMN2 4269/4885HSD17B10 643/4885
US-20110059976-A1 PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF AURKA 232/4885SMN1; SMN2 3919/4885HSD17B10 4083/4885
US-20120172290-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS AURKA 2747/4885SMN1; SMN2 4141/4885HSD17B10 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.